GSK vs. AZN, ITH, SOPH, HCM, INDV, GRI, SLS, ERGO, SLN, and AMYT
Should you be buying GSK stock or one of its competitors? The main competitors of GSK include AstraZeneca (AZN), Ithaca Energy (ITH), Sophos Group plc (SOPH.L) (SOPH), HUTCHMED (HCM), Indivior (INDV), Grainger (GRI), Standard Life UK Smaller Companies Trust (SLS), Ergomed (ERGO), Silence Therapeutics (SLN), and Amryt Pharma (AMYT). These companies are all part of the "pharmaceutical products" industry.
GSK vs. Its Competitors
GSK (LON:GSK) and AstraZeneca (LON:AZN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.
GSK pays an annual dividend of GBX 0.62 per share and has a dividend yield of 0.0%. AstraZeneca pays an annual dividend of GBX 3.14 per share and has a dividend yield of 0.0%. GSK pays out 75.0% of its earnings in the form of a dividend. AstraZeneca pays out 59.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
56.9% of GSK shares are held by institutional investors. Comparatively, 67.8% of AstraZeneca shares are held by institutional investors. 0.2% of GSK shares are held by company insiders. Comparatively, 0.1% of AstraZeneca shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
GSK currently has a consensus price target of GBX 1,637.50, suggesting a potential upside of 0.77%. AstraZeneca has a consensus price target of £134.25, suggesting a potential upside of 7.51%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than GSK.
In the previous week, GSK had 1 more articles in the media than AstraZeneca. MarketBeat recorded 12 mentions for GSK and 11 mentions for AstraZeneca. GSK's average media sentiment score of 0.68 beat AstraZeneca's score of -0.03 indicating that GSK is being referred to more favorably in the media.
GSK has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.
AstraZeneca has a net margin of 13.01% compared to GSK's net margin of 8.02%. GSK's return on equity of 18.08% beat AstraZeneca's return on equity.
Summary
AstraZeneca beats GSK on 11 of the 18 factors compared between the two stocks.
Get GSK News Delivered to You Automatically
Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools
This page (LON:GSK) was last updated on 10/17/2025 by MarketBeat.com Staff